AmbiJet
Financiado
AmbiJet: the world’s first and only highly effective plasma-based solution for E...
AmbiJet: the world’s first and only highly effective plasma-based solution for Europe’s 16 Million periimplantitis patients urgently needing help to avoid losing their dental implant
Regular dental check-ups and treatments not only ensure a beautiful smile, but good general health: a healthy oral cavity strengthens the immune system and acts as a barrier against various heart-, kidney-, or lungs-related diseas...
Regular dental check-ups and treatments not only ensure a beautiful smile, but good general health: a healthy oral cavity strengthens the immune system and acts as a barrier against various heart-, kidney-, or lungs-related diseases and diabetes. There is currently no effective solution to treat the 16.3 mn infected dental implants (EU, 2019). Freiburger Medizintechnik GmbH developed the solution dentists are looking for: a disruptive technology for highly effective infection control to fight periimplantitis. AmbiJet® is the world’s first and only plasma-based technology with the ability to kill bacteria on dental implants in-situ. It disrupts the status-quo of medical technologies by preventing the reinfection of disinfected surfaces and shows maximum effectiveness without side nor adverse effects: pharmacological and chemical substances are no longer required. AmbiJet® reduces inflammation, saves dental implants and helps patients live a healthier life.
ver más
Duración del proyecto: 24 meses
Fecha Inicio: 2022-09-14
Fecha Fin: 2024-09-30
Fecha Fin: 2024-09-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2022-ACCELERATOROPEN-01:
EIC Accelerator Open
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
FREIBURGER MEDIZINTECHNIK GMBH
No se ha especificado una descripción o un objeto social para esta compañía.
